Transactions on Cancer (2024)
Clausius Scientific Press, Canada

DOI: 10.23977/tranc.2024.050113
ISSN 2523-6482 Vol. 5 Num. 1

Research Progress on the Application of Electronic Bronchoscopy Based on Next-Generation Sequencing (NGS) Technology

Yiting Wang

Department of Respiratory and Critical Care Medicine, The Second People's Hospital of Baoshan, Baoshan, Yunnan, 678000, China

Keywords: Bronchoscopy; Next Generation Sequencing (NGS); Pulmonary Diseases; Personalized Medicine

Abstract: This comprehensive article explores the integration of Next Generation Sequencing (NGS) with bronchoscopic techniques to enhance the diagnosis and management of pulmonary diseases. NGS provides detailed genetic insights into various conditions, such as lung cancer and pulmonary fibrosis, enabling the identification of genetic mutations, pathogen detection, and the development of personalized treatment strategies. The technology's ability to process and analyze large volumes of genetic data rapidly has transformed pulmonary oncology by facilitating the early detection of tumors, precise molecular profiling, and targeted therapy selection. Additionally, NGS aids in diagnosing infectious diseases and non-neoplastic conditions like sarcoidosis by identifying causative pathogens and genetic predispositions. Despite the promising applications, challenges such as high costs, complex data interpretation, and technical demands limit wider adoption. However, ongoing advancements are expected to lower these barriers, making NGS a cornerstone in future pulmonary medicine, significantly advancing precision medicine and improving patient outcomes.

1. Introduction

Bronchoscopy represents a pivotal diagnostic tool in pulmonology, allowing direct visualization of the bronchial tree. This endoscopic technique is essential for assessing airway anatomy and pathology, facilitating biopsies, and other therapeutic interventions. The integration of Next Generation Sequencing (NGS) technology with bronchoscopic procedures marks a significant advancement in the molecular diagnosis of pulmonary diseases. NGS enables the comprehensive analysis of genetic information from minute bronchoscopic samples, providing a profound depth of data that traditional methodologies cannot achieve[1].

The application of NGS in this context enhances the diagnostic accuracy for a range of pulmonary conditions, including lung cancer and tuberculosis. By enabling the detailed examination of genetic mutations, gene expression profiles, and other genomic alterations, NGS facilitates the identification of disease-specific biomarkers[2]. This capability is crucial not only for confirming diagnoses but also for tailoring personalized treatment strategies. For instance, in lung cancer, identifying specific

oncogenic drivers can guide the selection of targeted therapies, thereby improving therapeutic outcomes[3].

Furthermore, NGS can detect a broad spectrum of pathogens directly from bronchial washings or biopsies, offering a significant advantage in diagnosing infectious diseases. Traditional microbiological techniques, which rely on culture, are often time-consuming and may not detect non-culturable or fastidious organisms. NGS overcomes these limitations by identifying microbial DNA or RNA sequences, thus providing a faster and more comprehensive approach to diagnosing infections[4].

The synergy of bronchoscopy and NGS represents a transformative approach to pulmonary medicine, enhancing diagnostic precision and enabling more personalized management of lung diseases. As this technology continues to evolve and become more accessible, its integration into routine clinical practice promises to revolutionize the diagnosis and treatment of a wide array of pulmonary pathologies[5].

2. The principles and development of NGS technology

Next Generation Sequencing (NGS) technology represents a monumental leap in the field of genomics, offering the ability to rapidly and efficiently sequence vast amounts of DNA and RNA. This method utilizes high-throughput sequencing platforms that facilitate the simultaneous processing of multiple samples, dramatically accelerating the genomic data acquisition process. Unlike traditional Sanger sequencing, which sequences DNA fragments one at a time, NGS parallelizes the sequencing process, allowing for the sequencing of millions of fragments concurrently. This approach not only speeds up the sequencing process but also reduces the cost per base of DNA sequenced[6].

The development of NGS technology began in the early 2000s, transforming genomic studies and clinical diagnostics. By reading hundreds of millions to billions of base pairs in a matter of hours, NGS enables a deeper exploration into the genetic architecture of organisms and diseases. This has significant implications for clinical research, particularly in understanding complex diseases such as cancer, genetic disorders, and infectious diseases. The depth of sequencing provided by NGS allows for the detection of rare genetic variants, precise profiling of genetic mutations, and comprehensive analysis of gene expression patterns[7].

Furthermore, NGS has facilitated the development of personalized medicine by providing the tools necessary to tailor medical treatment to the individual genetic profile of patients. In oncology, for example, NGS is used to identify actionable mutations that can be targeted by specific drugs, thus optimizing therapeutic strategies and improving patient outcomes[8].

The continuous advancements in NGS technology, including improvements in accuracy, speed, and cost-efficiency, are expanding its applications in biomedical research and beyond. As NGS becomes more accessible and integrated into clinical practice, it promises to further revolutionize our understanding and management of genetic and complex diseases[9].

3. The application of NGS in bronchoscopy

The integration of Next Generation Sequencing (NGS) with bronchoscopic techniques has significantly advanced the field of pulmonary oncology by enhancing the diagnostic precision and therapeutic targeting of lung cancer. Lung cancer, characterized by its heterogeneity and complex genetic underpinnings, presents significant challenges in diagnosis and treatment. The ability to perform detailed genetic analyses through NGS on samples obtained via bronchoscopy has opened new avenues for personalized medicine in this domain[9].

3.1 Lung Cancer Diagnosis

Bronchoscopy is an indispensable tool in pulmonology, particularly valuable for its ability to provide direct visual and physical access to the pulmonary airways. This capability is critical in the diagnosis of lung cancer, as it allows for the collection of tissue samples from tumors, including those located in peripheral regions of the lungs that are often unreachable by traditional, non-surgical diagnostic methods[2,10].

3.1.1 Sample Collection and Genetic Analysis

The procedure involves inserting a bronchoscope through the mouth or nose, navigating down the throat and into the airways of the lungs. This minimally invasive approach enables pulmonologists to collect samples directly from tumor sites without the need for more invasive surgical interventions. Once tissue samples are obtained, they are subject to rigorous genetic analysis using Next Generation Sequencing (NGS) technologies[11].

NGS plays a transformative role at this juncture by sequencing the DNA and RNA extracted from the collected cells. This sequencing process is highly detailed, offering a panoramic view of the genetic mutations present in the cancer cells. NGS can detect a wide array of genetic abnormalities, from common mutations that frequently appear in lung cancer populations to rare or novel mutations that may be specific to an individual's tumor[8].

3.1.2 Impact of Early and Accurate Mutation Identification

(1) Early Detection: Identifying genetic mutations early in the disease course allows for a more precise diagnosis, often before extensive spread occurs, thereby improving the chances for successful treatment outcomes [8].

(2) Targeted Therapy Selection: The detailed genetic data provided by NGS enables oncologists to select targeted therapies that are most likely to be effective against the specific genetic drivers of a patient's cancer. For instance, if a tumor harbors an EGFR mutation, therapies designed to inhibit EGFR can be employed, which are often more effective and have fewer side effects than conventional chemotherapy [4].

(3) Prognostic Value: Certain genetic markers can also provide prognostic information, helping to predict how aggressive the cancer is likely to be and informing decisions about the intensity of needed treatments [5].

3.1.3 Advanced Molecular Profiling in Lung Cancer

Molecular profiling using Next Generation Sequencing (NGS) provides a comprehensive analysis of the genetic anomalies associated with lung cancer, offering insights far beyond the detection of simple mutations. This detailed profiling includes the examination of gene fusions and variations in gene expression, which are integral to understanding the pathogenesis and progression of lung cancer [6].

The ability to identify mutations in critical oncogenes such as EGFR, KRAS, ALK, and ROS1 through NGS has transformed the landscape of lung cancer treatment. Each of these genes, when mutated, can significantly alter the behavior of cancer cells [12]:

(1) EGFR Mutations: These are some of the most common genetic changes in lung cancer, particularly in non-small cell lung cancer (NSCLC). Mutations in the EGFR gene lead to the continuous activation of the growth signals in cells, promoting uncontrolled proliferation. Tyrosine kinase inhibitors (TKIs), which specifically target and inhibit the EGFR protein, can effectively halt the progression of cancer in patients harboring these mutations [13].

(2) KRAS Mutations: While currently fewer targeted therapies are available for KRAS-driven tumors, the identification of KRAS mutations is crucial for prognosis and treatment planning, as these are often associated with resistance to EGFR-targeted therapies [14].

(3) ALK and ROS1 Rearrangements: These genetic alterations involve the rearrangement of the ALK or ROS1 genes, leading to fusion proteins that drive malignant growth. Targeted therapies that inhibit these fusion proteins have shown remarkable efficacy in treating tumors with these specific genetic profiles [15].

3.1.4 Importance of Gene Fusions

Gene fusions, such as the EML4-ALK fusion in NSCLC, represent another critical target detected through NGS. The fusion of the EML4 and ALK genes creates a new oncogene that can be effectively targeted by ALK inhibitors. The detection of such fusions is essential as it allows for the use of specific inhibitors that can significantly improve patient outcomes. NGS is adept at identifying these fusions, even when they occur at low frequencies within the tumor cell population, which is a substantial advantage over traditional diagnostic methods [16, 17].

3.1.5 Gene Expression Analysis

Beyond mutations and fusions, NGS also allows for the quantification of gene expression levels, providing insights into the active biological pathways in tumor cells. This level of analysis helps in understanding the tumor environment and can guide the use of drugs that target specific pathways involved in cancer cell survival and proliferation [18, 19].

3.1.6 Impact on Treatment Selection

The detailed molecular insights provided by NGS influence the therapeutic approach significantly. By understanding the specific genetic alterations within a tumor, oncologists can tailor treatment strategies to target the underlying molecular mechanisms of the disease effectively. This personalized approach not only enhances the efficacy of the treatment but also minimizes potential side effects by avoiding ineffective therapies.

The use of NGS in bronchoscopic procedures is continually evolving, with ongoing research aimed at increasing the sensitivity and specificity of genetic analyses. Future developments are expected to streamline the workflow and reduce the costs associated with NGS, making it a more accessible option for routine clinical practice. Moreover, as more targeted therapies become available, the role of NGS in guiding clinical decisions will likely expand, further cementing its value in the management of lung cancer [5,8].

3.2 Enhanced Detection of Microbial Infections in Pulmonary Medicine

Next Generation Sequencing (NGS) has revolutionized the field of infectious disease diagnostics, particularly in the detection and characterization of pathogens in pulmonary conditions. Using bronchial samples obtained via bronchoscopy, NGS enables the analysis of both DNA and RNA from a wide array of microorganisms, including bacteria, viruses, fungi, and other pathogens [20].

3.2.1 Comprehensive Pathogen Detection via Next Generation Sequencing

Next Generation Sequencing (NGS) provides an expansive approach to pathogen detection, characterized by its unbiased methodology that does not require specific primers or probes. This approach stands in contrast to traditional microbiological techniques such as culture-dependent methods and polymerase chain reaction (PCR), which typically target a limited range of pathogens

based on pre-established clinical suspicions[21].

3.2.2 Unbiased Detection across a Broad Spectrum

NGS can sequence all nucleic acids present in a sample, providing a holistic overview of the microbial community. This includes not only the common pathogens but also non-culturable organisms, rare variants, and newly emerging microbes. Such capability is crucial in cases where the infectious agent is unknown or unexpected, which can often occur in immunocompromised patients or those with complex clinical histories [22].

3.2.3 Applications in Atypical and Nonspecific Infections

Patients presenting with atypical or nonspecific symptoms pose a significant diagnostic challenge. Symptoms like fever, cough, or respiratory distress may be caused by a wide array of pathogens, and traditional diagnostics may fail to identify the causative agent if it is not one commonly associated with such clinical presentations. NGS sidesteps these limitations by providing a diagnostic net wide enough to capture all potential pathogens, thereby offering a more definitive diagnosis and enabling appropriate treatment [23].

3.2.4 Detection of Novel and Rare Pathogens

The emergence of novel pathogens and the occurrence of rare or exotic infections are of particular concern in global health. Traditional methods may be poorly equipped to identify such pathogens due to the absence of specific diagnostic tools. NGS, however, can rapidly identify novel genetic signatures even if the pathogen itself has never been characterized before. This was notably beneficial during the outbreak of new diseases like COVID-19, where NGS played a pivotal role in quickly identifying the SARS-CoV-2 virus and tracking its mutations [24].

3.2.5 Enhancing Epidemiological Surveillance

NGS also enhances epidemiological surveillance and response strategies by identifying the presence and spread of pathogens within populations. This technology can detect slight genetic variations among pathogens, which helps in tracking transmission pathways and understanding the epidemiology of infectious diseases at both local and global scales [25].

3.2.6 Quantitative and Qualitative Insights from NGS

NGS transcends traditional pathogen detection methods by not only confirming the presence of pathogens but also quantifying their abundance in a sample. This quantitative analysis is vital for assessing the severity of infections and can influence the intensity of treatment regimens. For example, a high microbial load in bronchial samples might suggest an aggressive infection requiring more robust antimicrobial therapy [26].

Moreover, NGS offers qualitative insights that are equally critical. By sequencing the entire genome of microbes present, NGS can identify antimicrobial resistance genes that may not be detected by conventional susceptibility tests. This knowledge allows clinicians to tailor antibiotic therapy to the specific resistance patterns of the pathogens, avoiding ineffective treatments and reducing the risk of developing further resistance [27].

Additionally, NGS characterizes virulence factors, which are genetic elements that contribute to a pathogen's ability to cause disease. Understanding which virulence factors are present can help predict the pathogen's behavior and potential complications, guiding more informed clinical decisions[28].

3.2.7 Application in Complex Clinical Cases

The application of Next Generation Sequencing (NGS) in managing complex clinical cases offers significant benefits, particularly for immunocompromised patients and those with chronic pulmonary diseases such as cystic fibrosis or chronic obstructive pulmonary disease (COPD). These individuals are frequently susceptible to a wide range of pathogens, including typical bacteria, atypical organisms, and opportunistic pathogens that often escape detection with standard diagnostic tools. NGS's broad-spectrum detection capabilities allow for the identification of multiple pathogens from a single sample, enhancing the diagnostic process and avoiding delays in initiating appropriate treatment. This is crucial for these vulnerable populations, where timely and accurate treatment is essential[29]. Moreover, NGS's ability to detect polymicrobial infections, which are common in patients with advanced chronic diseases, is invaluable for formulating effective treatment strategies[30].

In these scenarios, NGS facilitates a personalized approach to treatment, enabling clinicians to tailor antibiotic regimens based on a detailed understanding of the microbial landscape and specific resistance mechanisms within each patient. This tailored approach not only improves the effectiveness of treatments but also contributes to better management of chronic conditions, potentially reducing hospital stays and enhancing the quality of life for these patients. By providing both extensive pathogen detection and deep insights into microbial characteristics, NGS stands as a transformative tool in pulmonary infection management, particularly where traditional methods may be inadequate[31]. As such, NGS continues to redefine the limits of microbial diagnostics and patient-specific therapy planning, pushing the boundaries of precision medicine in infectious disease management.

3.3 Pulmonary fibrosis and other non-neoplastic diseases

Next Generation Sequencing (NGS) significantly enhances the diagnosis and treatment of pulmonary fibrosis and other non-neoplastic diseases by identifying genetic mutations and pathogens that influence disease progression. This detailed genetic insight allows for personalized treatment strategies, advancing precision medicine in pulmonary care and improving patient outcomes.

3.3.1 Pulmonary fibrosis

NGS technology has become a pivotal tool in understanding the complex molecular landscape of various pulmonary diseases, especially those that are non-neoplastic such as pulmonary fibrosis. Pulmonary fibrosis involves progressive and irreversible scarring of lung tissue, which can significantly impair respiratory function. The etiology of pulmonary fibrosis can be multifactorial, including genetic predispositions, environmental exposures, and autoimmune components.

By analyzing genetic markers in bronchoalveolar lavage fluid or tissue samples, NGS provides comprehensive insights into the genetic and molecular alterations associated with the development and progression of pulmonary fibrosis. This includes the identification of mutations in genes like TERT, TERC, SFTPC, and MUC5B, which have been linked to familial forms of the disease. Moreover, NGS can detect subtle changes in gene expression patterns and epigenetic modifications that contribute to fibrotic processes[32]. This level of detail is crucial for understanding the pathogenesis of the disease, which is often obscured in routine clinical evaluations.

NGS also plays a crucial role in identifying the presence of specific pathogens that may trigger or exacerbate pulmonary fibrosis. For instance, chronic viral infections or unrecognized fungal infections can contribute to the fibrotic process, and their detection through NGS can influence the direction of therapeutic interventions, potentially guiding the use of antiviral or antifungal treatments[33].

3.3.2 Non-neoplastic diseases

In diseases like sarcoidosis, another non-neoplastic pulmonary condition characterized by the formation of granulomas, NGS can be used to analyze granuloma-derived DNA to identify potential infectious causes or genetic predispositions that might drive the granulomatous reaction[34]. This helps in differentiating sarcoidosis from other granulomatous diseases like tuberculosis or fungal infections, which is often challenging with traditional diagnostic methods.

The use of NGS in these contexts not only aids in diagnosis but also enhances the ability to tailor specific therapies based on the underlying genetic and molecular profile of the disease. This precision medicine approach can lead to better management strategies, aiming to halt the progression or even reverse the fibrotic changes, thereby improving patient outcomes[35].

In summary, the integration of NGS into the diagnostic workflow for pulmonary fibrosis and similar non-neoplastic diseases represents a significant advancement in pulmonary medicine. It provides a deeper understanding of disease mechanisms, supports accurate diagnosis, and facilitates the development of personalized therapeutic strategies, ultimately leading to improved clinical management of these challenging conditions.

4. Current Challenges

The integration of Next Generation Sequencing (NGS) with bronchoscopy offers transformative potential for diagnosing and treating pulmonary diseases, yet several challenges inhibit its broader adoption. High operational costs present a significant barrier due to the expensive sequencing technology and the need for specialized equipment. Furthermore, the complexity of data interpretation requires sophisticated bioinformatics expertise, posing a hurdle for many medical facilities. Technical demands for meticulous sample handling and processing also mean that only highly specialized centers can effectively implement these procedures [2,9].

5. Future Prospects

Despite these challenges, the outlook for NGS in bronchoscopy is optimistic, driven by rapid advancements in technology. Ongoing innovations are expected to reduce costs and enhance the efficiency of NGS, making it more accessible. As the technology becomes more widespread, economies of scale may further decrease expenses, facilitating integration into routine clinical practice. This progress promises to significantly enhance precision medicine, allowing for treatments tailored to the genetic profiles of individual patients' conditions. Over time, as the barriers of cost and complexity diminish, NGS is poised to revolutionize the management of respiratory diseases, improving outcomes through more precise diagnoses and personalized treatment strategies.

In summary, while current challenges are substantial, the potential for NGS to transform pulmonary medicine is immense. Continued technological development and integration into clinical practice are expected to unlock significant benefits for the diagnosis and treatment of lung diseases, ultimately leading to better patient care and outcomes [36,37].

References

[1] Zhong Y, Xu F, Wu J, Schubert J, Li M. Application of Next Generation Sequencing in Laboratory Medicine[J]. Annals of Laboratory Medicine, 2021, 41(1):25-43.

[2] Akkari Y, Smith T, Westfall J, Lupo S. Implementation of cancer next-generation sequencing testing in a community hospital[J]. Cold Spring Harbor Molecular Case Studies, 2019, 5.

[3] Teixeira M, Oliveira J, Borralho P, Fernandes M, Almodovar T, Fernandes I, et al. Portuguese Consensus Recommendations for Next-Generation Sequencing of Lung Cancer, Rare Tumors, and Cancers of Unknown Primary

Origin in Clinical Practice[J]. Acta medica portuguesa, 2022.677-690
[4] Wensel C, Pluznick J, Salzberg S, Sears C. Next-generation sequencing: insights to advance clinical investigations of the microbiome[J]. The Journal of Clinical Investigation, 2022, 132.
[5] Hicks J, Howard R, Reisman P, Adashek J, Fields K, Gray J, et al. Integrating Somatic and Germline Next-Generation Sequencing Into Routine Clinical Oncology Practice[J]. JCO Precision Oncology, 2021, 5:884-895.
[6] Satam H, Joshi K, Mangrolia U, Waghoo S, Zaidi G, Rawool S, et al. Next-Generation Sequencing Technology: Current Trends and Advancements[J]. Biology, 2023, 12(7).997
[7] Kumar K, Cowley M, Davis R. Next-Generation Sequencing and Emerging Technologies[J]. Seminars in Thrombosis and Hemostasis, 2019, 45:661-673.
[8] Mosele F, Remon J, Mateo J, et al. Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group[J]. Annals of Oncology, 2020, 31(11): 1491-1505.
[9] Zhong Y, Xu F, Wu J, Schubert J, Li M. Application of Next Generation Sequencing in Laboratory Medicine[J]. Annals of Laboratory Medicine, 2021, 41(1):25-43.
[10] Colomer R, Mondejar R, Romero-Laorden N, et al. When should we order a next generation sequencing test in a patient with cancer?[J]. EClinicalMedicine, 2020, 25.
[11] Kunimasa K, Matsumoto S, Nishino K, et al. Improvement strategies for successful next-generation sequencing analysis of lung cancer[J]. Future Oncology, 2020, 16(22): 1597-1608.
[12] Christofyllakis K, Bittenbring J T, Thurner L, et al. Cost-effectiveness of precision cancer medicine-current challenges in the use of next generation sequencing for comprehensive tumour genomic profiling and the role of clinical utility frameworks[J]. Molecular and Clinical Oncology, 2022, 16(1): 1-4.
[13] Jin Y, Weng Y, Xu Z, Peng M. Research progress on targeted treatment in ROS1-positive non-small cell lung cancer[J]. Journal of International Oncology, 2020, 46:745-749.
[14] Reck M, Carbone D, Garassino M, Barlesi F. Targeting KRAS in non-small cell lung cancer: recent progress and new approaches[J]. Annals of Oncology, 2021, 32:741-751.
[15] Remon J, Pignataro D, Novello S, Passiglia F. Current treatment and future challenges in ROS1- and ALK-rearranged advanced non-small cell lung cancer [J]. Cancer Treatment Reviews, 2021, 95:102178.
[16] Li W, Liu Y, Li W, et al. Intergenic breakpoints identified by DNA sequencing confound targetable kinase fusion detection in NSCLC[J]. Journal of Thoracic Oncology, 2020, 15(7): 1223-1231.
[17] De Luca C, Pepe F, Iaccarino A, et al. RNA-based assay for next-generation sequencing of clinically relevant gene fusions in non-small cell lung cancer[J]. Cancers, 2021, 13(1): 139.
[18] Uhrig S, Ellermann J, Walther T, et al. Accurate and efficient detection of gene fusions from RNA sequencing data[J]. Genome research, 2021, 31(3): 448-460.
[19] Cohen D, Hondelink L M, Solleveld-Westerink N, et al. Optimizing mutation and fusion detection in NSCLC by sequential DNA and RNA sequencing[J]. Journal of Thoracic Oncology, 2020, 15(6): 1000-1014.
[20] Chen Y, Feng W, Ye K, et al. Application of metagenomic next-generation sequencing in the diagnosis of pulmonary infectious pathogens from bronchoalveolar lavage samples[J]. Frontiers in cellular and infection microbiology, 2021, 11: 541092.
[21] Huang J, Jiang E, Yang D, et al. Metagenomic next-generation sequencing versus traditional pathogen detection in the diagnosis of peripheral pulmonary infectious lesions[J]. Infection and drug resistance, 2020: 567-576.
[22] Wei P, Wu L, Li Y, et al. Metagenomic next-generation sequencing for the detection of pathogenic microorganisms in patients with pulmonary infection[J]. American Journal of Translational Research, 2022, 14(9): 6382.
[23] Shao J, Hassouna A, Wang Y, et al. Next-generation sequencing as an advanced supplementary tool for the diagnosis of pathogens in lower respiratory tract infections: An observational trial in Xi'an, China[J]. Biomedical Reports, 2022, 16(2): 1-9.
[24] Yang A, Chen C, Hu Y, et al. Application of metagenomic next-generation sequencing (mNGS) using bronchoalveolar lavage fluid (BALF) in diagnosing pneumonia of children[J]. Microbiology Spectrum, 2022, 10(5): 1-11.
[25] Knyazev S, Hughes L, Skums P, et al. Epidemiological data analysis of viral quasispecies in the next-generation sequencing era[J]. Briefings in bioinformatics, 2021, 22(1): 96-108.
[26] Florensa A F, Kaas R S, Clausen P T L C, et al. ResFinder–an open online resource for identification of antimicrobial resistance genes in next-generation sequencing data and prediction of phenotypes from genotypes[J]. Microbial Genomics, 2022, 8(1): 000748.
[27] Ternus K L, Keplinger N C, Kappell A D, et al. Detection of ESKAPE pathogens and Clostridioides difficile in Simulated Skin Transmission Events with Metagenomic and Metatranscriptomic Sequencing[J]. bioRxiv, 2021: 2021.03. 04.433847.
[28] Ferreira I, Lepuschitz S, Beisken S, et al. Culture-free detection of antibiotic resistance markers from native patient samples by hybridization capture sequencing [J]. Microorganisms, 2021, 9(8): 1672.
[29] Ahmad A, Hettiarachchi R, Khezri A, et al. Highly sensitive quantitative phase microscopy and deep learning aided

with whole genome sequencing for rapid detection of infection and antimicrobial resistance[J]. Frontiers in Microbiology, 2023, 14: 1154620.
[30] Zhou L, Lopez Rodas A, Llangar íL M, et al. Single gene targeted nanopore sequencing enables simultaneous identification and antimicrobial resistance detection of sexually transmitted infections[J]. Plos one, 2022, 17(1): e0262242.
[31] Gali K V, St. Jacques R M, Daniels C I D, et al. Surveillance of carbapenem-resistant organisms using next-generation sequencing[J]. Frontiers in Public Health, 2023, 11: 1184045.
[32] Karman J, Wang J, Bodea C, et al. Lung gene expression and single cell analyses reveal two subsets of idiopathic pulmonary fibrosis (IPF) patients associated with different pathogenic mechanisms[J]. PLoS One, 2021, 16(3): e0248889.
[33] Wang C, You Z, Fu J, et al. Application of metagenomic next-generation sequencing in the diagnosis of pulmonary invasive fungal disease[J]. Frontiers in Cellular and Infection Microbiology, 2022, 12: 949505.
[34] Fran ̧oise A, H ́y-Arnaud G. The microbiome in cystic fibrosis pulmonary disease[J]. Genes, 2020, 11(5): 536.
[35] Samarelli A V, Masciale V, Aramini B, et al. Molecular mechanisms and cellular contribution from lung fibrosis to lung cancer development[J]. International journal of molecular sciences, 2021, 22(22): 12179.
[36] Tiew P Y, Meldrum O W, Chotirmall S H. Applying next-generation sequencing and multi-omics in chronic obstructive pulmonary disease[J]. International journal of molecular sciences, 2023, 24(3): 2955.
[37] Vanderpoel J, Stevens A L, Emond B, et al. Total cost of testing for genomic alterations associated with next-generation sequencing versus polymerase chain reaction testing strategies among patients with metastatic non-small cell lung cancer [J]. Journal of Medical Economics, 2022, 25(1): 457-468.